神经药理学报 ›› 2025, Vol. 15 ›› Issue (6): 42-.DOI: 10.3969/j.issn.2095-1396.2025.06.006

• 研究论文 • 上一篇    下一篇

草酸艾司西酞普兰联合米氮平治疗方案用于抑郁症睡眠障碍患者睡眠调节与抑郁症状缓解效果研究

隗春玲,艾明亮   

  1. 1. 北京市房山区精神卫生保健院精神科,北京,102405,中国 

    2. 首都医科大学附属北京安定医院精神科,北京,102405,中国

  • 出版日期:2025-12-26 发布日期:2026-03-30
  • 通讯作者: 艾明亮,主治医师,硕士研究生;研究方向:精神病学
  • 作者简介:隗春玲,副主任医师,本科

Study on the Effect of Citalopram Combined with Mirtazapine Treatment Regimen on Sleep Regulation and Relief of Depressive Symptoms in Patients with Sleep Disorders Caused by Depression

KUI Chun-ling, AI Ming-liang   

  1. 1. Department of Psychiatry, Beijing Fangshan Mental Health Hospital, Beijing, 102405, China 

    2. Department of Psychiatry, Beijing Anding Hospital Affiliated to Capital Medical University, Beijing, 102405, China

  • Online:2025-12-26 Published:2026-03-30

摘要:

目的:探讨对抑郁症睡眠障碍患者实施西酞普兰联合米氮平治疗对其睡眠调节、抑郁症状缓解的效果。 方法:选取100 例于2022 年6 月至2025 年6 月在北京市房山区精神卫生保健院治疗的抑郁症伴有睡眠障碍患 者,按随机数表法分作两组,对照组(50 例)单独行草酸艾司西酞普兰治疗,观察组(50 例)行草酸艾司西酞普兰 合并米氮平治疗,对比两组的睡眠调节效果、抑郁症状缓解效果、总体疗效及不良反应。结果:观察组治疗后的匹 兹堡睡眠质量指数量表(pittsburgh sleep quality index,PSQI)总分是(9.89±1.21)分,低于对照组的(12.68±1.08) 分(P < 0.05);观察组治疗后的17 项汉密尔顿抑郁量表(17-item hamilton depression scale,HAMD-17)总分是 (11.38±1.20)分,临床总体印象量表-病情严重程度(clinical global impressions scale,CGI-S)总分是( 3.32±0.42) 分,分别低于对照组的(13.49±1.12)分、(4.11±0.45)分;观察组的总有效率(94.00%)高于对照组(80.00%)(P < 0.05);观察组的不良反应(6.00%)与对照组(4.00%)对比,差异无统计学意义(P > 0.05)。结论:对抑郁症睡眠 障碍展开治疗时,联用草酸艾司西酞普兰与米氮平可促进睡眠调节、抑郁症状缓解效果进一步提升,达到良好总 体疗效,且具备理想安全性。

关键词: 草酸艾司西酞普兰, 米氮平, 抑郁症, 睡眠障碍, 睡眠调节, 抑郁症状

Abstract:

Objective: To explore the effect of citalopram combined with mirtazapine on sleep regulation and relief of depressive symptoms in patients with sleep disorders caused by depression. Methods: 100 cases of patients with sleep disorders caused by depression who were admitted to our hospital from June 2023 to June 2025 were selected, they were according to the digital random table method divided into two groups , 50 cases in the control group were treated alone with citalopram, 50 cases in the observation group were treated with citalopram and mirtazapine,the sleep regulation effects, relief effects of depressive symptoms, overall therapeutic effects and adverse reactions of the two groups were compared. Results: In the observation group, the total score of the pittsburgh sleep quality index (PSQI) after treatment was (9.89±1.21) points, which was lower than (12.68±1.08) points that of the control group (P<0.05). In the observation group, the scores of the 17-item hamilton depression scale (HAMD-17) after treatment were (11.38±1.20) points,the clinical overall impression scale-severity of Illness (CGI-S) was (3.32±0.42) points,which were lower than (13.49±1.12) points and (4.11±0.45) points in the control group (P<0.05). In the observation group, the total effective rate (94.00%) was higher than control group (80.00%) (P<0.05). There was no statistically significant difference in adverse reactions between the observation group (6.00%) and the control group (4.00%) (P>0.05). Conclusion: When treating sleep disorders caused by depression, the combined use of escitalopram oxalate and mirtazapine can further enhance the effect of sleep regulation and relief of depressive symptoms, achieving a good overall therapeutic effect and having ideal safety.

Key words: citalopram, mirtazapine, depression, sleep disorder, sleep regulation, depressive symptoms

中图分类号: